Background: Artemisia Capillaris Formula (ACF), a traditional Chinese medicinal therapy, has been used clinically in China to treat
NAFLD in SD rats consisted of 87.3% basal fodder, 10% lard, 2% cholesterol and 0.7% swine bile salt. After an 8-week feeding period, the rats fed with the HFD were randomly divided into 5 groups: the untreated HFD model group (model), the polyene phosphatidylcholine-treated group (PP), and the ACF-treated groups (high-, medium-and low-dose) (10 rats/group). The drug regimen involved the intra-gastric administration of either PP (76 mg/kg body weight/day), ACF high-dose (1.848 g/kg body weight/day), ACF middle-dose (0.924 g/kg body weight/day) or ACF low-dose (0.462 g/kg body weight/day) during weeks 5−8 of the 8 week protocol. The HFD model group and the standard diet control group received distilled water. The body weight and food uptake were recorded weekly. All rats were sacrificed by decapitation after 4 hours of food deprivation. Blood samples were collected for analysis of ALT, AST, ALP, TG, TC, HDL-C and LDL-C levels. The liver was sectioned and processed, either by fixation in formaldehyde (4%) in isotonic saline for histological analysis, or by quick-freezing in liquid nitrogen and storage at -80°C.
Histological Examination
Sections of liver tissue were fixed in formaldehyde (4%) in isotonic saline and embedded in paraffin. 6 serial sections of 5 μm thickness each per tissue were prepared from 10 rats per group and subsequently deparaffinized in xylene, rehydrated in graded ethanol; then stained with hematoxylin and eosin (H&E) for histological observation under a light microscope.
Biochemical Assays
Whole blood samples were incubated at room temperature for 2 h, followed by centrifugation at 3000 rpm for 20 min at 4℃ to separate the fractions. Serum fractions were collected and stored at -20℃. Serum ALT, AST, ALP, TG, TC, HDL-C and LDL-C levels were measured using commercially available kits and following the manufacturer's instructions.
RNA Extraction and RT-PCR Analysis
Total RNA was isolated from fresh liver tissue with TRIzol Reagent according to the manufacturer's protocol. Oligo(dT)-primed RNA (1 µg) was reverse-transcribed using the PrimeScript™ RT reagent Kit with gDNA Eraser. The resulting cDNA was used for PCR. GAPDH was used as an internal control. The primers used for amplification of FAS, ACC, CPT and GAPDH genes were: FAS F: 5'-CCT TAG TAC TGC GTG GTC GTA T-3', R: 5'-CAG AGG GTG CTT GTT AGA AAG AT-3′ (301 bp); ACC F: 5'-TGA GGA GGA CCG CAT TTA TC-3', R: 5'-GAA GCT TCC TTC GTG ACC AG-3' (565 bp); CPT F: 5'-TAT GTG AGG ATG CTG CTT CC-3', R: 5'-CTC GGA GAG CTA AGC TTG TC-3'（629bp; GAPDH F: 5'-AGA TCC ACA ACG GAT-3', R: 5'-TCC CTC AAG ATT GTC AGC AA-3' (308bp). Amplification of each gene was performed with a thermal cycler (GE9600, USA), using the following cycling parameters: denaturing, 95°C for 3 min, 30 cycles of 95°C for 30 sec, annealing temperature for 30 sec and 72°C for 45 sec, followed by a final extension of 10 min at 72°C. Gene expression was determined for 6-8 samples randomly selected from each group, and each sample was run in triplicate. The PCR products were separated by electrophoresis on a 1.5% agarose gel. The DNA bands were examined using a Gel Documentation System (BioRad, Model Gel Doc 2000, USA).
Immunohistochemical Assay
The paraffin-embedded liver samples were sectioned (3 serial section of 5 μm thickness) from 10 rats per group. Sections were deparaffinized, rehydrated, submerged in 1% hydrogen peroxide; epitope retrieved, and then soaked in goat serum, followed by an overnight incubation with primary antibodies at 4˚C. The primary antibodies used in this study were polyclonal rabbit anti-rat FAS, ACC or CPT (1:200 dilutions, Santa Cruz Biotechnology). PBS served as a negative staining control. After primary antibody staining and washing with PBS, slides were incubated with a biotin-labelled secondary antibody followed by a further incubation with conjugated horseradish peroxidase (HRP)-labelled streptavidin (Dako). Slides were washed with PBS and counterstained with DAB chromogen, according to the manufacturer's
The following abbreviations are used to describe each treatment group: PP (polyene phosphatidylcholine group); ACF-L (ACF low dose group); ACF-M (ACF medium dose group); ACF-H (ACF high dose group). Model group showed severe degree of micro-and macro-vesicular-steatosis (black arrow), hepatocellular ballooning (red arrow).
ACF Altered the Levels of Serum ALT, AST, ALP, TG, TC, HDL-C and LDL-C in NAFLD Rats.
As shown in Fig. 2A , the activities of serum ALT, AST, and ALP were significantly elevated in the HFD-fed model group compared with the control group (p < 0.05). Compared to model group rats, the activities of these serum transaminases were significantly decreased in ACF high-, medium-and low-treatment groups, as well as in HFD-fed rats treated with the hepato-protective drug polyene phosphatidylcholine (PP) (p < 0.05). Serum TG and TC levels were significantly increased in model group rats compared with control group rats (p < 0.05), but TG and TC levels were significantly decreased in ACF or PP-treated rats when compared to the model group (p < 0.05). Similarly, serum LDL-C levels were significantly increased in model group rats compared with the control group (p < 0.05), but these levels were significantly decreased in ACF or PP-treated rats compared with the model group (p < 0.05). In contrast, serum HDL-C levels were significantly decreased in model group rats compared with the control group (p < 0.05), but there was no significant difference in HDL-C levels between the model group, ACF treatment groups, or the PP treatment group (Fig. 2B) .
ACF Regulates the Expression of FAS, ACC and CPT in Rats.
To determine the mechanism responsible for the ameliorative effect of ACF on HFD-induced hepatosteatosis, we evaluated gene and protein expression levels of three enzymes associated with fatty acid synthesis or oxidation: FAS, ACC and CPT. Gene expression levels were measured from hepatic tissue using RT-PCR, and quantitative immunohistochemistry was used for in situ assessment of protein expression levels in liver sections from each treatment group. The mRNA levels of FAS and ACC, as well as protein levels in hepatic tissue, were significantly increased in the model group compared with the control group (p < 0.05) (Fig. 3 and Fig. 4) . Compared to the model group, expression levels of these enzymes were significantly decreased in the ACF-treated rats (p < 0.05). In contrast, both mRNA and protein expression levels of CPT were significantly decreased in the model group compared with the control group (p < 0.05), and increased in the ACF treatment group. Taken together, these observations suggest that ACF treatment significantly reversed changes in expression patterns of ACC, FAS and CPT induced by NAFLD in HFD-fed rats (P<0.05), and ACF treatment was able to restore enzymatic expression in HFD-fed rats to similar levels as in the control group.
Discussion
The prevalence of NAFLD has reached epidemic proportions in recent years due to the increasing prevalence of obesity and metabolic syndrome worldwide. NAFLD is the most common cause of abnormal liver function and chronic liver disease in both developed and developing countries (Yilmaz et al., 2012) . It includes variable degrees of simple steatosis (fatty liver), non-alcoholic steatohepatitis (NASH) and cirrhosis. produced by ACC inhibits the activity of CPT1, and thereby decreases the rate of β-oxidation by reducing fatty acid entry into the mitochondria.
Thus, FAS, ACC and CPT are closely correlated with the occurrence of NAFLD (Saha et al., 2003) , and these enzymes may provide the crucial link between NAFLD pathology and lipid metabolism that is targeted by ACF. Our results support this hypothesis through the observation that ACF treatment reduced both gene and protein expression levels of FAS and ACC, as well as increased the expression of CPT in the liver tissues of NAFLD rats (Figures 3 and 4) .
In conclusion, the present study demonstrates the ameliorative potential of Artemisia Capillaris Formula on HFD-induced NAFLD in SD rats and indicates a potential mechanism of action that involves regulation of lipid metabolism.
